Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Evidence that elevated lipoprotein (a)(Lp [a]) levels contribute to cardiovascular disease
(CVD) and calcific aortic valve stenosis (CAVS) is substantial. Development of isoform …

Background Lipoprotein (a) levels are genetically determined and, when elevated, are a risk
factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic …

Background Elevated lipoprotein (a) is a genetic risk factor for cardiovascular disease in
general population studies. However, its contribution to risk for cardiovascular events in …

Background: Elevated lipoprotein (a)[Lp (a)] is a prevalent, independent cardiovascular risk
factor, but the underlying mechanisms responsible for its pathogenicity are poorly defined …

Lipoprotein (a)[Lp (a)] has attracted the interest of researchers and physicians due to its
intriguing properties, including an intragenic multiallelic copy number variation in the LPA …

Pathophysiological, epidemiological, and genetic studies provide strong evidence that
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …

Lipoprotein (a)(Lp (a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to
apolipoprotein (a). Increased Lp (a) levels are an independent, heritable causal risk factor …

Background Laboratory methods that report low-density lipoprotein cholesterol (LDL-C)
include both LDL-C and lipoprotein (a) cholesterol [Lp (a)-C] content. Objectives The …

Summary Background Lipoprotein (a)(Lp [a]) is a risk factor for cardiovascular disease and
calcific aortic valve stenosis. No effective therapies to lower plasma Lp (a) concentrations …